Calquence (acalabrutinib) FDA Approval Timeline
Calquence, the brand name for acalabrutinib, received its initial U.S. Food and Drug Administration (FDA) approval on October 31, 2017 [1]. This approval was for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy [1].
When Did Calquence Get Approved for Chronic Lymphocytic Leukemia?
Acalabrutinib was later approved for chronic lymphocytic leukemia (CLL) on June 20, 2019 [2]. This expanded indication included adult patients with previously treated or untreated CLL [2]. The drug also gained approval for small lymphocytic lymphoma (SLL) on the same date [2].
What Are the Indications for Calquence?
Currently, Calquence is approved for adult patients with:
* Mantle cell lymphoma (MCL) who have received at least one prior therapy [1].
* Chronic lymphocytic leukemia (CLL) [2].
* Small lymphocytic lymphoma (SLL) [2].
Who Manufactures Calquence?
Calquence is manufactured by AstraZeneca [3].
How Does Acalabrutinib Work?
Acalabrutinib is a targeted therapy that acts as a Bruton's tyrosine kinase (BTK) inhibitor [1][2]. BTK is a protein that plays a crucial role in the development and function of certain white blood cells, including B cells, which are involved in the immune response [1][2]. In certain types of lymphoma and leukemia, BTK is overactive, promoting the growth and survival of cancer cells [1][2]. By inhibiting BTK, acalabrutinib disrupts these signaling pathways, leading to reduced proliferation and increased apoptosis (cell death) of cancerous B cells [1][2].
What Are the Common Side Effects of Calquence?
Common side effects associated with Calquence treatment include fatigue, headache, diarrhea, muscle pain, and bruising [1][2]. More serious side effects can include infections, bleeding events, cardiac arrhythmias, and secondary primary malignancies [1][2]. Patients should discuss potential side effects with their healthcare provider.
What Are the Patent Expirations for Acalabrutinib?
Information regarding specific patent expiration dates for acalabrutinib can be found through resources like DrugPatentWatch.com [4]. Patent information is complex and can involve multiple patents covering different aspects of the drug, including its composition of matter, manufacturing processes, and methods of use. These patents can have varying expiration dates, and their duration can be extended through mechanisms such as patent term extensions, which are often granted to compensate for time lost during the FDA approval process [4].
What Are the Competitors to Calquence?
Key competitors to acalabrutinib in the treatment of CLL and MCL include other BTK inhibitors such as ibrutinib (Imbruvica) and zanubrutinib (Brukinsa) [5]. Other treatment options may include chemotherapy, immunotherapy, and other targeted therapies, depending on the specific cancer type and patient's disease stage and prior treatments [5].
What Clinical Data Supports Calquence's Approval?
The FDA approvals for Calquence were based on clinical trial data demonstrating its efficacy and safety. For MCL, the approval was supported by a study showing significant response rates in patients with relapsed or refractory MCL [1]. For CLL and SLL, approvals were based on trials that demonstrated acalabrutinib's effectiveness in both previously treated and untreated patients, often showing comparable or improved outcomes to existing therapies in terms of progression-free survival and overall response rates [2].
What Are the Concerns Regarding Acalabrutinib's Long-Term Use?
Long-term safety and efficacy data continue to be gathered for acalabrutinib. Ongoing research focuses on monitoring for potential late-emerging side effects, such as secondary primary malignancies, cardiovascular events, and the development of resistance to the therapy [1][2]. The management of these potential long-term issues is a crucial aspect of patient care.
*
**Sources:
[1] FDA approval of Calquence for MCL: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-calquence-acalabrutinib-mantle-cell-lymphoma
[2] FDA approval of Calquence for CLL and SLL: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-calquence-acalabrutinib-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma
[3] AstraZeneca official website: https://www.astrazeneca.com/
[4] DrugPatentWatch.com: https://drugpatentwatch.com/
[5] Comparison of BTK inhibitors: (General knowledge of the oncology drug market, specific comparative studies would be required for direct citation of competitive data within this context)